CFTR and cystic fibrosis: In two 52-week, randomized, double-blind, active-controlled trials (Trial 1, NCT05033080; Trial 2, NCT05076149), the efficacy of ALYFTREK and Trikafta was evaluated in 971 patients aged 12 years and older with cystic fibrosis who had at least one F508del mutation or an adaptive CFTR gene mutation [197].